DXCM: 10-K Risk Factor Changes

2024 vs 2023  ·  SEC EDGAR  ·  2026-05-22
Other years: 2026 vs 2025 · 2025 vs 2024
⚠ AI-Generated

The summary below was generated by an AI language model and may contain errors or omissions. All other content on this page is deterministically extracted from the original SEC EDGAR filing.

DXCM deprioritized pandemic-specific risk disclosure by replacing a detailed COVID-19 risk with a broader public health risks statement, reflecting a shift away from coronavirus-specific concerns. The company added a new financial risk related to capped call transactions tied to its 2028 convertible notes, indicating evolving capital structure complexities. Eight substantive modifications to existing risks - including product liability, stock volatility, and data privacy - suggest DXCM refined its risk characterizations to reflect current operational and regulatory conditions.

✓ Deterministic extraction — no AI-generated data

Classification is based on semantic text similarity scoring and may include approximations. “No match” means no high-confidence textual match was found — not necessarily that a section was removed.

2
New Risks
2
Removed
8
Modified
67
Unchanged
🟢 New in Current Filing We are subject to risks associated with public health issues, including pandemics, which could have a material adverse effect on our business, financial condition and results of operations. 🔒
🟢 New in Current Filing The capped call transactions we entered into in connection with the pricing of the 2028 Notes may affect the value of our 2028 Notes and common stock. 🔒
🔴 No Match in Current Filing The outbreak of the SARS-CoV-2 virus and its variants and the COVID-19 disease that it causes, or similar public health crises, could have a material adverse impact on our business, financial condition and results of operations, including our manufacturing, commercial operations and sales. 🔒
🔴 No Match in Current Filing Valuation of share-based payments, which we are required to perform for purposes of recording compensation expense under authoritative guidance for share-based payment, involves assumptions that are subject to change and difficult to predict. 🔒
🟡 Modified We face the risk of product liability claims and may be subject to damages, fines, penalties and injunctions, among other things. 🔒
🟡 Modified Our stock price is highly volatile and investing in our stock involves a high degree of risk, which could result in substantial losses for investors. 🔒
🟡 Modified We are subject to complex and evolving U.S. and foreign laws and regulations and other requirements regarding privacy, data protection, security, and other matters. Many of these laws and regulations are subject to change and uncertain interpretation, and could result in claims, changes to our business practices, monetary penalties, increased cost of operations, or declines in user growth or engagement, or otherwise harm our business. 🔒
🟡 Modified Laws and regulations governing the export of our products could adversely impact our business. 🔒
🟡 Modified Security breaches and other disruptions that compromise our information and expose us to liability could cause our business and reputation to suffer and could subject us to substantial liabilities. 🔒
🟡 Modified We could be subject to changes in our tax rates, new U.S. or international tax legislation or additional tax liabilities. 🔒
🟡 Modified The warrants related to the 2023 Notes and our common stock. 🔒
🟡 Modified We are subject to counterparty risk with respect to the 2028 Capped Calls. 🔒
12 changes in this historical filing

Historical year-over-year comparisons (2024 vs 2023 and earlier) are available on the Pro plan.

Get full access — from $29/month Already a Pro subscriber? View full diff →